SignalDailyGlobal signals. Global context.

Market Incident

Public · Developing

AI compiled from Infoway · 5 analyzed stories

Sun Pharma Ordered To Halt Eye Drug Output At Assam Plant

Drug regulators ordered Sun Pharmaceutical Industries to halt manufacture, sale and distribution of ophthalmic products from its Assam facility after finding quality management failures. The 20 August order followed a joint inspection and a July voluntary recall of around 11 eye-care brands.

Published:

Updated:

What happened

Indian drug regulators ordered Sun Pharmaceutical Industries to stop making, selling and distributing eye-care products from its Assam plant. The order followed an inspection that found serious quality-management gaps and a July voluntary recall of about 11 eye-care brands. The company says it is taking remedial action.

Global impact / market context

The order prevents eye-care products from this plant being made, sold or distributed for now. The supplied information does not say how this will affect the company’s wider business or give details of the reported problems.

What to watch

  1. Check whether regulators change the order; this shows whether the restriction remains in place.
  2. Check whether Sun Pharma reports progress on its remedial action; this shows how it is responding to the quality concerns.
  3. Check for further details about the July recall and the review of 332 batches; these could clarify the scope of the concerns.

Affected assets

  • Sun Pharmaceutical Industries Ltd

Evidence